Global Viral Respiratory Infections Treatment Market, By Treatment Type (Antiviral Medications, Vaccine, Monoclonal Antibodies, Non-steroidal Anti-inflammatory Drugs (NSAIDs), and Others), Type (OTC and Prescription Based), Route of Administration (Oral, Nasal, and Injectable), Disease Type (Covid, Influenza (FLU), Respiratory Syncytial Virus (RSV), Parainfluenza, Adenoviruses, Rhinovirus (Common Cold), Enterovirus, Anti-inflammatory, and Others), Infection Type (Upper Respiratory Infections and Lower Respiratory Infections), Population (Pediatric, Adults, and Geriatric), Gender (Male and Female), End User (Hospitals, Home Care Settings, Clinics, Research Institutes and Academic Centers, and Ambulatory Surgical Centers), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031.
Viral Respiratory Infections Treatment Market Analysis and Size
The increasing prevalence of viral respiratory infections is driving the market growth. However, stringent regulatory approval processes are restraining the market growth. On the other hand, the rising collaborative research activities and partnerships are expected to create opportunities for market growth.
Data Bridge Market Research analyzes that the global viral respiratory infections treatment market is expected to reach USD 108,207.05 million by 2031 from USD 57,365.34 million in 2023, growing at a CAGR of 8.5% in the forecast period of 2024 to 2031.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Treatment Type (Antiviral Medications, Vaccine, Monoclonal Antibodies, Non-steroidal Anti-inflammatory Drugs (NSAIDs), and Others), Type (OTC and Prescription Based), Route of Administration (Oral, Nasal, and Injectable), Disease Type (Covid, Influenza (FLU), Respiratory Syncytial Virus (RSV), Parainfluenza, Adenoviruses, Rhinovirus (Common Cold), Enterovirus, Anti-inflammatory, and Others), Infection Type (Upper Respiratory Infections and Lower Respiratory Infections), Population (Pediatric, Adults, and Geriatric), Gender (Male and Female), End User (Hospitals, Home Care Settings, Clinics, Research Institutes and Academic Centers, and Ambulatory Surgical Centers), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel and Rest of Middle East and Africa
|
|
Market Players Covered
|
Pfizer Inc., GSK plc, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Inc., SINOVAC FAMILY, Lilly, AstraZeneca, Regeneron Pharmaceuticals Inc., Bharat Biotech., Swedish Orphan Biovitrum AB (publ), Serum Institute of India Pvt. Ltd., Biological E Limited, Celltrion Healthcare Co.,Ltd., InflaRx N.V. and among others
|
Market Definition
Treatment for viral respiratory infections includes a wide range of medical procedures intended to fight diseases caused by viruses that impact the respiratory system. Many ailments, including the common cold, influenza (flu),Respiratory Syncytial Virus (RSV), adenovirus, and more recently, new viruses such as SARS-CoV-2, which is responsible for COVID-19, are caused by these illnesses, which mostly affect the nose, throat, sinuses, and lungs. A variety of strategies are usually used to treat these illnesses, such as antiviral drugs, supportive care to reduce symptoms, immunization to ward off particular diseases, and, in more serious situations, hospitalization with cutting-edge techniques such as oxygen therapy or mechanical ventilation. The development of novel antiviral medications, vaccinations, and therapeutic approaches to improve treatment efficacy, lessen symptom intensity, and stop the transmission of these extremely contagious respiratory infections is constantly fueled by advances in medical science.
Global Viral Respiratory Infections Treatment Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Prevalence of Viral Respiratory Infections
The rising incidence of respiratory infections including influenza, Respiratory Syncytial Virus (RSV), and the global impact of the COVID-19 pandemic, has fueled the demand for effective treatment options. The expanding global population, coupled with factors such as urbanization and international travel, has contributed to the rapid spread of respiratory viruses, creating a substantial patient pool in need of therapeutic interventions.
- Government Initiatives and Vaccination Programs
Governments around the world are implementing strategic initiatives to curb the spread of viral respiratory infections by recognizing the significant impact of these diseases on public health. One of the most effective measures has been the promotion and widespread implementation of vaccination programs aimed at preventing key viral respiratory infections such as influenza, pneumonia, and COVID-19. Governments are investing substantial resources to ensure the broad accessibility and affordability of vaccines, contributing to increased vaccination coverage globally.
Opportunity
- Rising Collaborative Research Activities and Partnerships
A multidisciplinary strategy combining partnerships between pharmaceutical companies, academic institutions, governments, and healthcare organizations is necessary due to the complexity of viral respiratory diseases. Collaborative research initiatives that combine resources, information, and skills accelerate the speed of innovation in viral respiratory infection treatments. Collaborations facilitate the exchange of information, scientific discoveries, and innovations in technology, leading to a more thorough comprehension of viruses, their workings, and possible therapeutic approaches. These partnerships provide the way to more effective medication development and discovery procedures. Compared to working alone, researchers can find new therapeutic targets, create innovative antiviral drugs, and develop vaccination technologies more quickly and efficiently when they bring together various perspectives and specialized knowledge.
Restraint/Challenge
- Dependency on Skilled Medical Personnel
The effective diagnosis and treatment of viral respiratory infections often require a high level of expertise and experience among healthcare professionals. The shortage of skilled personnel, particularly in certain regions, causes hindrance to the seamless delivery of healthcare services and limits the market's potential for growth.
The complexity of managing viral respiratory infections, including accurate diagnosis, appropriate treatment selection, and patient care, demands a workforce with specialized skills. The shortage of qualified healthcare professionals, such as infectious disease specialists, pulmonologists, and respiratory therapists, hampers the timely and efficient delivery of healthcare services. This dependency on a skilled workforce creates a bottleneck in regions where there is a scarcity of specialized medical personnel.
Recent Developments
- In August 2023, Regeneron Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority (BARDA) entered into an agreement for a new COVID-19 monoclonal antibody therapy for the prevention of SARS-CoV-2 infection being supported in its clinical development, clinical manufacturing, and regulatory licensure process
- In July 2023, SINOVAC and PT Biofarma announced a major step forward in the two businesses' cooperative efforts to service Indonesia's home vaccination market and the global market
Global Viral Respiratory Infections Treatment Market Scope
The global viral respiratory infections treatment market is segmented into nine notable segments based on treatment type, type, route of administration, disease type, infection type, population, gender, end user, and distribution channel.
Treatment Type
- Antiviral Medications
- Vaccine
- Monoclonal Antibodies
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Others
On the basis of treatment type, the market is segmented into antiviral medications, vaccine, monoclonal antibodies, non-steroidal anti-inflammatory drugs (NSAIDs), and others.
Type
- OTC
- Prescription-Based
On the basis of type, the market is segmented into OTC and prescription-based.
Route of Administration
- Oral
- Nasal
- Injectable
On the basis of route of administration, the market is segmented into oral, nasal, and injectable.
Disease Type
- Covid
- Influenza (FLU)
- Respiratory Syncytial Virus (RSV)
- Parainfluenza
- Adenoviruses
- Rhinovirus (Common Cold)
- Enterovirus
- Others
On the basis of disease type, the market is segmented into covid, influenza (flu), respiratory syncytial virus (RSV), parainfluenza, adenoviruses, rhinovirus (common cold), enterovirus, and others.
Infection Type
- Upper Respiratory Infections
- Lower Respiratory Infections
On the basis of infection type, the market is segmented into upper respiratory infections and lower respiratory infections.
Population
- Pediatric
- Adults
- Geriatric
On the basis of population, the market is segmented into pediatric, adults, and geriatric.
Gender
- Male
- Female
On the basis of gender, the market is segmented into male and female.
End User
- Hospitals
- Home Care Settings
- Clinics
- Research Institutes and Academic Centers
- Ambulatory Surgical Centers
On the basis of end user, the market is segmented into hospitals, home care settings, clinics, research institutes and academic centers, and ambulatory surgical centers.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others.
Global Viral Respiratory Infections Treatment Market Regional Analysis/Insights
The global viral respiratory infections treatment market is segmented into nine notable segments based on treatment type, type, route of administration, disease type, infection type, population, gender, end user, and distribution channel.
The countries covered in this market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel and Rest of Middle East and Africa.
North America is expected to dominate the market due to large investments with rising technological advancements. The U.S. is expected to dominate in the North America region as it possesses a sophisticated healthcare system characterized by advanced medical facilities, cutting-edge research institutions, and a well-established regulatory framework. Germany is expected to dominate in the Europe region due to its exceptional healthcare infrastructure, a concentration of leading pharmaceutical companies, stringent regulatory standards, strategic geographic positioning, and a proactive stance on public health. China is expected to dominate in the Asia-Pacific region as it has a rapidly expanding pharmaceutical sector with a focus on innovation. The presence of both domestic and international pharmaceutical companies has contributed to a dynamic ecosystem that encourages the development of novel antiviral drugs and therapeutics.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Viral Respiratory Infections Treatment Market Share Analysis
The global viral respiratory infections treatment market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the market.
Some of the major market players operating in the global viral respiratory infections treatment market are Pfizer Inc., GSK plc, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Inc., SINOVAC FAMILY, Lilly, AstraZeneca, Regeneron Pharmaceuticals Inc., Bharat Biotech., Swedish Orphan Biovitrum AB (publ), Serum Institute of India Pvt. Ltd., Biological E Limited, Celltrion Healthcare Co.,Ltd., InflaRx N.V. and among others.
SKU-